eMedicine Specialties > Dermatology > Benign Neoplasms

Leiomyoma

Author: Kyle L Horner, MD, MS, Staff Physician, Department of Dermatology, Penn State Milton S Hershey Medical Center
Coauthor(s): Gregory J Raugi, MD, PhD, Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle; Marion C Miethke, MD, Clinical Assistant Professor, Department of Internal Medicine, Section of Dermatology, University of Washington
Contributor Information and Disclosures

Updated: Sep 22, 2009

Introduction

Background

Leiomyomas are benign soft tissue neoplasms that arise from smooth muscle; they were first described by Virchow1 in 1854. The hereditary form, which causes, multiple leiomyomas, was originally noted by Kloepfer et al2 in 1958. They can develop wherever smooth muscle is present. Malignant transformation probably does not occur. A 2006 report3 of a cutaneous leiomyosarcoma with myxoid alteration in a scar of a piloleiomyoma that had been excised 3 years previously probably does not represent a case of malignant transformation.

Also see Esophageal Leiomyoma; Leiomyoma, Iris; and Leiomyoma, Uterus (Fibroid).

Pathophysiology

Three fairly distinct types of cutaneous leiomyomas exist: piloleiomyomas, angioleiomyomas, and genital leiomyomas. This classification reflects the most logical origin of the smooth muscle tumor and corresponds to the histologic or anatomic site where the leiomyomas are found. Piloleiomyomas are believed to arise from the arrector pili muscle of the pilosebaceous unit, whereas angioleiomyomas originate from smooth muscle (ie, tunica media) within the walls of arteries and veins. Leiomyomas derived from the dartos muscle of the scrotum and the labia majora, as well as those derived from the erectile muscle of the nipple, are classified as genital leiomyomas. Tumors in each classification have distinct clinical and/or histologic characteristics.

The pathogenesis of leiomyomas remains obscure. Angioleiomyomas and genital leiomyomas usually occur as solitary lesions, whereas piloleiomyomas may be either solitary or multiple, at times numbering in the thousands. The arrector pili muscle, from which piloleiomyomas originate, attaches proximally to the hair follicle and distally to multiple attachment points within the papillary and reticular dermis, as well as to the basement membrane. Piloleiomyomas can plausibly emerge from each of these various points of insertion and occur as multiple tumors. Multiple lesions can be inherited as an autosomal-dominant trait with variable penetrance, or they can occur sporadically. Unfortunately, even less is known about the potential pathophysiologic or genetic features of other leiomyomas.

The pathogenesis of pain associated with these lesions is also a mystery. Some authors have suggested that pain could result from local pressure by the tumor on cutaneous nerves. However, the histologic findings do not show that prominent nerve fibers are associated with these tumors. Others have theorized that specific infiltrating cells may play a role; one study of 24 angioleiomyomas revealed that painful tumors had fewer mast cells than asymptomatic ones. Yet others have suggested that muscle contraction may be pivotal in the induction of pain.

The excitation of the arrector pili muscle occurs via the sympathetic nervous system. Norepinephrine, secreted by postganglionic nerve fibers, activates the alpha-receptors of the muscle. Muscle contraction ensues; this is triggered by the influx of ions, most specifically calcium. Understanding this basic physiologic process may be relevant to the medical treatment of symptomatic leiomyomas.

Leiomyomas may be categorized into the following 4 types:

  • Multiple piloleiomyomas
  • Solitary piloleiomyoma
  • Angioleiomyoma (solitary)
  • Genital leiomyoma (solitary)

Frequency

United States

Leiomyomas are uncommon. Genital leiomyomas tend to be the least common of the 3 types.

International

International frequency data does not differ from the US frequency data.

Mortality/Morbidity

Because cutaneous leiomyomas are benign tumors, they do not directly affect mortality. However, one case report3 involves an angioleiomyoma that occurred in association with a leiomyosarcoma. The relevance of this association is unknown.

Associated morbidity may be due to spontaneous lesional pain, as well as pain evoked by cold and/or tactile hypersensitivity. Additionally, multiple piloleiomyomas have the potential to be cosmetically disfiguring.

Race

A racial predilection is not described, except in regard to oral angioleiomyomas, for which the white-to-black ratio has been reported4 to be 3:1

Sex

The incidences of piloleiomyomas in men and women appear to be about equal. Women who have multiple cutaneous piloleiomyomas may also have uterine leiomyomas. If the latter are present, the patient most likely has a familial condition called familial leiomyomatosis cutis et uteri, or Reed syndrome. Reed syndrome is thought to be inherited as an autosomal-dominant trait with incomplete penetrance. As such, not all women in a family are affected, and those who are may have only cutaneous, only uterine, or both cutaneous and uterine leiomyomas.

Angioleiomyomas are more common in women than in men, with a ratio of 2:1 overall, however the solid subtype occurs more commonly in females (3:1), the venous subtype occurs more commonly in males, and the least common of the three, the cavernous subtype, is four times more common in males.5,6

Because genital leiomyomas are rare, data to determine whether a sexual predilection exists are inadequate.

Age

Cutaneous leiomyomas are more likely to occur in adults than in children. However, isolated reports of cutaneous leiomyomas in children exist, including one involving a nonspecified type of solitary cutaneous leiomyoma on the heel of a neonate at birth.

  • Multiple piloleiomyomas generally occur in those aged 10-30 years. When solitary, piloleiomyomas usually appear later. For example, in a series of 28 solitary cutaneous leiomyomas, the mean patient age at presentation was 53 years.
  • Angioleiomyomas most often occur in those aged 20-60 years, although some investigators report a narrower window of increased incidence in those aged 20-40 years. In a retrospective clinicopathologic analysis of 562 angioleiomyomas, the mean age of the patients was 47 years; their overall age range was 12-84 years.
  • Leiomyomas typified as genital leiomyomas are rare enough that an age predilection is not generally described.

Clinical

History

  • The most common feature in patients with multiple piloleiomyomas is pain.
    • Pain can be spontaneous or induced by cold or tactile (eg, pressure) stimuli.
    • The pain or tenderness may be secondary to pressure on nerve fibers within the tumor; however, some authors believe it may be solely due to contraction of muscle fibers.5
  • Many solitary piloleiomyomas are similarly symptomatic.
  • About 60% of angioleiomyomas are symptomatic.6 Pain in angioleiomyomas may be due to nerve fibers in the stroma or wall of the tumors or perhaps due to the contraction of blood vessels with local ischemia.5
  • In addition to the previously described trigger factors (ie, temperature and pressure), symptoms are also reported to occur with menses or pregnancy.
  • Genital leiomyomas are usually asymptomatic solitary lesions arising from the dartoic, vulvar, or mamillary muscles in the genital region or on the nipple.7

Physical

  • Individual piloleiomyomas are smooth, firm papules or nodules, usually smaller than 2 cm in diameter, and reddish brown. Many are tender to palpation.
    • Multiple piloleiomyomas can occur on the face, trunk, or extremities. Various distribution patterns are reported, including bilaterally symmetric, grouped, dermatomal, and linear patterns.
    • A solitary piloleiomyoma is usually found on a lower extremity.
    • Because piloleiomyomas develop in the superficial dermis, they are fixed in the skin. However, they can be easily moved over the deeper subcutaneous tissues.
These multiple hyperpigmented nodules are pilolei...

These multiple hyperpigmented nodules are piloleiomyomas on an upper extremity.

These multiple hyperpigmented nodules are pilolei...

These multiple hyperpigmented nodules are piloleiomyomas on an upper extremity.


Upon closer inspection, one can appreciate that t...

Upon closer inspection, one can appreciate that these piloleiomyomas are superficial dermal nodules.

Upon closer inspection, one can appreciate that t...

Upon closer inspection, one can appreciate that these piloleiomyomas are superficial dermal nodules.

  • Angioleiomyomas are usually well-defined, fairly deep dermal nodules that are smaller than 4 cm.
    • Pain to palpation is not uncommon.
    • Angioleiomyomas are generally solitary and occur predominantly on the lower extremities, less commonly on the head or trunk, and rarely on the hands or in the mouth.4,8,9
    • The most common clinical presentation of an angioleiomyoma is that of a solitary skin-colored nodule.
  • Leiomyomas of the vulva or scrotum may be larger than those already described above. Leiomyomas of the nipple and piloleiomyomas are generally similar in size.

Causes

Recent research has revealed the location of the gene for transmission of dominantly inherited, multiple cutaneous piloleiomyomas associated with uterine leiomyomas in female family members.

    • The gene was linked to band 1q42.3-q43. Haplotype construction and recombination analysis narrowed the locus to an approximately 14-centromere interval located between D1S517 on the centromeric side and D1S2842 on the telomeric side.
    • As reported by Alam et al,10 the locus is named MCUL1 for multiple cutaneous and uterine leiomyomata 1.
    • Studies of an extended family narrowed the locus further to a region of 4.55-7.17 centromere on chromosome 1. This gene encodes for fumarate hydratase (FH), an enzyme of the tricarboxylic acid cycle, which acts as a tumor suppressor. In families with multiple cutaneous and uterine leiomyomata (MCUL) and hereditary leiomyomatosis and renal cell cancer (HLRCC), FH missense mutations often occurred in fully conserved residues and in residues functioning in the substrate binding A-site, substrate-binding B-site, or subunit-interacting region. All missense mutations in these families were associated with decreased enzyme activity, suggesting that the tumor suppressor role of FH is related to its enzymatic activity.11
    • A study of 108 affected individuals, including 46 probands and 62 affected relatives revealed that highly penetrant FH mutations underlie MCUL. Of women with FH mutations, 69% had both skin and uterine leiomyomas, 15% had only skin leiomyomas, and 7% had only uterine leiomyomas.12 Uterine leiomyomas not associated with skin leiomyomas were associated with the G354R FH mutation.
    • Cutaneous manifestations of HLRCC range from absent to severe cutaneous leiomyomas. Wei et al13 have so far identified 31 different germline FH mutations in 56 families with HLRCC. Six additional FH mutations have been described among Dutch and Spanish families with MCUL.14
    • A 2006 report described a unique clonal translocation (7;8)(p13;q11.2) in a leiomyoma of the vulva.15

More on Leiomyoma

Overview: Leiomyoma
Differential Diagnoses & Workup: Leiomyoma
Treatment & Medication: Leiomyoma
Follow-up: Leiomyoma
Multimedia: Leiomyoma
References

References

  1. Virchow R. Ueber Makroglossie und pathologische Neubildung quergestreifter Muskelfasern. Virchows Arch (Pathol Anat). 1854;7:126-38.

  2. Kloepfer HW, Krafchuk J, Derbes V. Hereditary multiple leiomyoma of the skin. Am J Hum Genet. Mar 1958;10(1):48-52. [Medline].

  3. Utikal J, Haus G, Poenitz N, Koenen W, Back W, Dippel E. Cutaneous leiomyosarcoma with myxoid alteration arising in a setting of multiple cutaneous smooth muscle neoplasms. J Cutan Pathol. Sep 2006;33 Suppl 2:20-3. [Medline].

  4. Brooks JK, Nikitakis NG, Goodman NJ, Levy BA. Clinicopathologic characterization of oral angioleiomyomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Aug 2002;94(2):221-7. [Medline].

  5. Holst VA, Junkins-Hopkins JM, Elenitsas R. Cutaneous smooth muscle neoplasms: clinical features, histologic findings, and treatment options. J Am Acad Dermatol. Apr 2002;46(4):477-90; quiz, 491-4. [Medline].

  6. Ramesh P, Annapureddy SR, Khan F, Sutaria PD. Angioleiomyoma: a clinical, pathological and radiological review. Int J Clin Pract. Jun 2004;58(6):587-91. [Medline].

  7. Gokdemir G, Sakiz D, Koslu A. Multiple cutaneous leiomyomas of the nipple. J Eur Acad Dermatol Venereol. Apr 2006;20(4):468-9. [Medline].

  8. Nagata S, Nishimura H, Uchida M, Hayabuchi N, Zenmyou M, Fukahori S. Giant angioleiomyoma in extremity: report of two cases. Magn Reson Med Sci. Jul 2006;5(2):113-8. [Medline].

  9. Yagi K, Hamada Y, Yasui N. A leiomyoma arising from the deep palmar arterial arch. J Hand Surg [Br]. Dec 2006;31(6):680-2. [Medline].

  10. Alam NA, Bevan S, Churchman M, Barclay E, Barker K, Jaeger EE, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet. May 2001;68(5):1264-9. [Medline].

  11. Alam NA, Olpin S, Rowan A, Kelsell D, Leigh IM, Tomlinson IP, et al. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J Mol Diagn. Oct 2005;7(4):437-43. [Medline].

  12. Alam NA, Olpin S, Leigh IM. Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer. Br J Dermatol. Jul 2005;153(1):11-7. [Medline].

  13. Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. Jan 2006;43(1):18-27. [Medline].

  14. Badeloe S, van Geel M, van Steensel MA, Bastida J, Ferrando J, Steijlen PM, et al. Diffuse and segmental variants of cutaneous leiomyomatosis: novel mutations in the fumarate hydratase gene and review of the literature. Exp Dermatol. Sep 2006;15(9):735-41. [Medline].

  15. Horton E, Dobin SM, Debiec-Rychter M, Donner LR. A clonal translocation (7;8)(p13;q11.2) in a leiomyoma of the vulva. Cancer Genet Cytogenet. Oct 1 2006;170(1):58-60. [Medline].

  16. Woertler K. Soft tissue masses in the foot and ankle: characteristics on MR Imaging. Semin Musculoskelet Radiol. Sep 2005;9(3):227-42. [Medline].

  17. Nakayama H, Enzan H, Miyazaki E, Kuroda N, Toi M. Lack of CD34 positive stromal cells within angiomyomas (vascular leiomyomas). J Clin Pathol. May 2002;55(5):395-6. [Medline].

  18. Batchelor RJ, Lyon CC, Highet AS. Successful treatment of pain in two patients with cutaneous leiomyomata with the oral alpha-1 adrenoceptor antagonist, doxazosin. Br J Dermatol. Apr 2004;150(4):775-6. [Medline].

  19. Alam M, Rabinowitz AD, Engler DE. Gabapentin treatment of multiple piloleiomyoma-related pain. J Am Acad Dermatol. Feb 2002;46(2 Suppl Case Reports):S27-9. [Medline].

  20. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol. Jun 2003;42(6):491-5. [Medline].

  21. Sifaki MK, Krueger-Krasagakis S, Koutsopoulos A, Evangelou GI, Tosca AD. Botulinum toxin type A--treatment of a patient with multiple cutaneous piloleiomyomas. Dermatology. 2009;218(1):44-7. [Medline].

  22. Onder M, Adisen E. A new indication of botulinum toxin: leiomyoma-related pain. J Am Acad Dermatol. Feb 2009;60(2):325-8. [Medline].

  23. Gravvanis A, Kakagia D, Papadopoulos S, Tsoutsos D. Dermal skin template for the management of multiple cutaneous leiomyomas. J Cutan Med Surg. Mar-Apr 2009;13(2):102-5. [Medline].

  24. Abraham Z, Cohen A, Haim S. Muscle relaxing agent in cutaneous leiomyoma. Dermatologica. 1983;166(5):255-6. [Medline].

  25. Archer CB, Greaves MW. Assessment of treatment for painful cutaneous leiomyomas [letter]. J Am Acad Dermatol. Jul 1987;17(1):141-2. [Medline].

  26. Archer CB, Whittaker S, Greaves MW. Pharmacological modulation of cold-induced pain in cutaneous leiomyomata. Br J Dermatol. Feb 1988;118(2):255-60. [Medline].

  27. Chuang GS, Martinez-Mir A, Geyer A, Engler DE, Glaser B, Cserhalmi-Friedman PB, et al. Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata. J Am Acad Dermatol. Mar 2005;52(3 Pt 1):410-6. [Medline].

  28. Fernandez-Pugnaire MA, Delgado-Florencio V. Familial multiple cutaneous leiomyomas. Dermatology. 1995;191(4):295-8. [Medline].

  29. Fitzpatrick JE, Mellette JR Jr, Hwang RJ, Golitz LE, Zaim MT, Clemons D. Cutaneous angiolipoleiomyoma. J Am Acad Dermatol. Dec 1990;23(6 Pt 1):1093-8. [Medline].

  30. García Muret MP, Pujol RM, Alomar A, Calaf J, de Moragas JM. Familial leiomyomatosis cutis et uteri (Reed's syndrome). Arch Dermatol Res. 1988;280 Suppl:S29-32. [Medline].

  31. Geddy PM, Gray S, Reid WA. Mast cell density and PGP 9.5-immunostained nerves in angioleiomyoma: their relationship to painful symptoms. Histopathology. Apr 1993;22(4):.5-immunostained nerves in angioleiomyoma: their relationship to painful sympto. [Medline].

  32. Laporte M, Achten G, Gheeraert P, Lowy M, Vokaer A. [Multiple leiomyoma treated with nifedipine: association with an astrocytoma]. Dermatologica. 1985;171(6):486-90. [Medline].

  33. Newman PL, Fletcher CD. Smooth muscle tumours of the external genitalia: clinicopathological analysis of a series [published erratum appears in Histopathology 1991 Aug;19(2):198]. Histopathology. Jun 1991;18(6):523-9. [Medline].

  34. Raj S, Calonje E, Kraus M, Kavanagh G, Newman PL, Fletcher CD. Cutaneous pilar leiomyoma: clinicopathologic analysis of 53 lesions in 45 patients. Am J Dermatopathol. Feb 1997;19(1):2-9. [Medline].

  35. Spencer JM, Amonette RA. Tumors with smooth muscle differentiation. Dermatol Surg. Sep 1996;22(9):761-8. [Medline].

  36. Thompson JA Jr. Therapy for painful cutaneous leiomyomas. J Am Acad Dermatol. Nov 1985;13(5 Pt 2):865-7. [Medline].

  37. Vellanki LS, Camisa C, Steck WD. Familial leiomyomata. Cutis. Jul 1996;58(1):80-2. [Medline].

  38. Venencie PY, Bigel P, de la Charrière O, Lemonnier V, Thébaut-Gerbaud D, Saurat JH. [Multiple cutaneous leiomyomatosis. Treatment with phenoxybenzamine]. Ann Dermatol Venereol. 1982;109(9):819-20. [Medline].

  39. Venencie PY, Puissant A, Boffa GA, Sohier J, Duperrat B. Multiple cutaneous leiomyomata and erythrocytosis with demonstration of erythropoietic activity in the cutaneous leiomyomata. Br J Dermatol. Oct 1982;107(4):483-6. [Medline].

Further Reading

Keywords

leiomyoma, angiomyoma, vascular leiomyoma, piloleiomyoma, pilar leiomyoma, genital leiomyoma, angioleiomyoma, cutaneous leiomyoma

Contributor Information and Disclosures

Author

Kyle L Horner, MD, MS, Staff Physician, Department of Dermatology, Penn State Milton S Hershey Medical Center
Kyle L Horner, MD, MS is a member of the following medical societies: American Academy of Dermatology, American Medical Association, and Pennsylvania Academy of Dermatology
Disclosure: Nothing to disclose.

Coauthor(s)

Gregory J Raugi, MD, PhD, Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle
Gregory J Raugi, MD, PhD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Marion C Miethke, MD, Clinical Assistant Professor, Department of Internal Medicine, Section of Dermatology, University of Washington
Marion C Miethke, MD is a member of the following medical societies: Phi Beta Kappa
Disclosure: Nothing to disclose.

Medical Editor

Carrie L Kovarik, MD, Assistant Professor of Dermatology, Dermatopathology, and Infectious Diseases, University of Pennsylvania School of Medicine
Carrie L Kovarik, MD is a member of the following medical societies: Alpha Omega Alpha
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Rosalie Elenitsas, MD, Herman Beerman Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System
Rosalie Elenitsas, MD is a member of the following medical societies: American Academy of Dermatology and American Society of Dermatopathology
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.